<?xml version='1.0' encoding='utf-8'?>
<document id="26124807"><sentence text="Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G."><entity charOffset="40-52" id="DDI-PubMed.26124807.s1.e0" text="ketoconazole" /><entity charOffset="80-89" id="DDI-PubMed.26124807.s1.e1" text="Gomisin G" /><pair ddi="false" e1="DDI-PubMed.26124807.s1.e0" e2="DDI-PubMed.26124807.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26124807.s1.e0" e2="DDI-PubMed.26124807.s1.e1" /></sentence><sentence text="Gomisin G, isolated from herb Schisandra chinensis, exhibits anti-tumor activities"><entity charOffset="0-9" id="DDI-PubMed.26124807.s2.e0" text="Gomisin G" /></sentence><sentence text=" Therefore, Gomisin G is a drug candidate for anti-liver cancer therapy"><entity charOffset="12-21" id="DDI-PubMed.26124807.s3.e0" text="Gomisin G" /></sentence><sentence text="" /><sentence text="To predict the metabolic behavior and metabolism-based drug-drug interaction of gomisin G" /><sentence text="" /><sentence text="Molecular docking method was used" /><sentence text=" The crystal structure of CYP3A4 with the ligand ketoconazole was chosen from protein data bank (http://www"><entity charOffset="49-61" id="DDI-PubMed.26124807.s8.e0" text="ketoconazole" /></sentence><sentence text="rcsb" /><sentence text="org/pdb)" /><sentence text=" Chemdraw software was used to draw the two-dimensional structure of gomisin G with standard bond lengths and angles"><entity charOffset="69-78" id="DDI-PubMed.26124807.s11.e0" text="gomisin G" /></sentence><sentence text="" /><sentence text="Gomisin G can be well docked into the activity site of CYP3A4, and distance between gomisin G the heme active site was 2"><entity charOffset="0-9" id="DDI-PubMed.26124807.s13.e0" text="Gomisin G" /></sentence><sentence text="75 Å" /><sentence text=" To evaluate whether the inhibitors of CYP3A4 can affect the metabolism of gomisin G, co-docking of gomisin G and ketoconazole was further performed"><entity charOffset="75-84" id="DDI-PubMed.26124807.s15.e0" text="gomisin G" /><entity charOffset="100-109" id="DDI-PubMed.26124807.s15.e1" text="gomisin G" /><entity charOffset="114-126" id="DDI-PubMed.26124807.s15.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.26124807.s15.e0" e2="DDI-PubMed.26124807.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26124807.s15.e0" e2="DDI-PubMed.26124807.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26124807.s15.e0" e2="DDI-PubMed.26124807.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26124807.s15.e1" e2="DDI-PubMed.26124807.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26124807.s15.e1" e2="DDI-PubMed.26124807.s15.e2" /></sentence><sentence text=" The distance between ketoconazole and activity center (2"><entity charOffset="22-34" id="DDI-PubMed.26124807.s16.e0" text="ketoconazole" /></sentence><sentence text="10 Å) is closer than the distance between gomisin G and activity center of CYP3A4, indicating the easy influence of CYP3A4's strong inhibitor towards the metabolism of gomisin G"><entity charOffset="42-51" id="DDI-PubMed.26124807.s17.e0" text="gomisin G" /></sentence><sentence text="" /><sentence text="Gomisin G is a good substrate of CYP3A4, and CYP3A4 inhibitors easily affect the metabolism of Gomisin G"><entity charOffset="0-9" id="DDI-PubMed.26124807.s19.e0" text="Gomisin G" /></sentence><sentence text="" /></document>